| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -18,676 | -16,058 |
| Proceeds from the exercise of common stock warrants (includes 4,960 in aggregate proceeds from related parties) | 35,745 | 35,745 |
| Proceeds from exercise of common stock options | 664 | 304 |
| Net cash provided by financing activities | 36,409 | 36,049 |
| Net decrease in cash and cash equivalents | -5,873 | 5,951 |
| Cash and cash equivalents at beginning of period | 8,740 | - |
| Cash and cash equivalents at end of period | 2,867 | - |
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)